

Date: June 12, 2025

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Scrip Code: 544250	The Secretary National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (E), Mumbai - 400 051 Symbol: SANOFICNR	Sanofi Consumer Healthcare India Limited Unit 1104, 11 th Floor, Godrej Two, Pirojshahnagar, Eastern Express Highway, Vikroli East, Mumbai, Maharashtra – 400 079
---	---	--

Sub.: Disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

Please find enclosed a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation to the acquisition of 25,04,630 equity shares of Sanofi Consumer Healthcare India Limited by Opal Bidco SAS pursuant to an open offer under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Thanking You.

Yours faithfully.

For **Opal Bidco SAS**



Opal Bidco SAS

By: Joao Paulo Alves Margarido

Title: Authorized Signatory

Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Sanofi Consumer Healthcare India Limited (“SCHIL”)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Opal Bidco SAS (“Acquirer”) PACs: Please refer to Note 1.		
Whether the acquirer belongs to Promoter/ Promoter group	Yes. The Acquirer is a member of the promoter group.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC
Before the acquisition under consideration, holding of acquirer of:			
a) Shares carrying voting rights	-	-	-
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/ convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	-	-	-
Details of acquisition			
a) Shares carrying voting rights acquired	25,04,630	10.87	10.87
b) VRs acquired otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	25,04,630	10.87	10.87
After the acquisition, holding of acquirer of:			
a) Shares carrying voting rights	25,04,630	10.87	10.87

b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	25,04,630	10.87	10.87
Mode of acquisition (e.g. open market/public issue/rights issue/preferential allotment/ inter-se transfer/encumbrance, etc.)	The Acquirer has directly acquired 25,04,630 equity shares of SCHIL pursuant to tendering of equity shares in an open offer under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“ SEBI SAST Regulations ”).		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not applicable		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares in the TC.	June 11, 2025		
Equity share capital of the TC before the said acquisition	2,30,30,622 equity shares of face value of INR 10 each as per the shareholding pattern of SCHIL for the quarter ended March 31, 2025		
Equity share capital of the TC after the said acquisition	2,30,30,622 equity shares of face value of INR 10 each as per the shareholding pattern of SCHIL for the quarter ended March 31, 2025		
Total diluted share of the TC after the said acquisition	2,30,30,622 equity shares of face value of INR 10 each as per the shareholding pattern of SCHIL for the quarter ended March 31, 2025		

Note 1 – Clayton, Dubilier & Rice Fund XII, L.P. was a person acting in concert with the Acquirer for the purpose of the open offer. The Acquirer is part of the Promoter Group of SCHIL.

Note 2 – The Acquirer indirectly acquired 100% of the shareholding of Opella Healthcare Participations BV, which owns 139,09,587 equity shares of SCHIL. This acquisition triggered an open offer under the SEBI SAST Regulations.

Note 3 – 25,04,630 equity shares were acquired by Opal Bidco SAS pursuant to the open offer resulting from the acquisition of Opella Healthcare Participations BV. The Acquirer directly and indirectly owns 1,64,14,217 equity shares (71.27%) of SCHIL.


Part-B*

Name of the Target Company: Sanofi Consumer Healthcare India Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/or PACs

*Part B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Signature of the Acquirer / Authorised Signatory
For and on behalf of **Opal Bidco SAS**

A handwritten signature in black ink, appearing to read "Paul-Henri Meyer". The signature is fluid and cursive, with the first name "Paul" and last name "Meyer" clearly distinguishable.

Authorized Signatory

Place: Luxembourg

Date: June 12, 2025